LEGAL, REGULATORY, EDITORIAL AND COMPLIANCE NOTICE (CAP CODE SECTION 12 - MEDICINES, MEDICAL DEVICES AND HEALTH)

POLICY - STATEMENT

This content is produced in accordance with recognised UK advertising, healthcare, and professional governance standards. In preparing and publishing blog and educational materials, Haus of Ästhetik Ltd has regard to, and seeks to operate within, the requirements and expectations of the following authorities and frameworks, where applicable:

• The UK Advertising Standards Authority (ASA)

• The Committee of Advertising Practice (CAP) Code, including the UK Advertising Codes (the "Blue Book" and "Red Book")

• Medicines and Healthcare products Regulatory Agency (MHRA) guidance on medicines and advertising

• Professional standards and guidance issued by relevant healthcare regulators, including the Nursing and Midwifery Council (NMC), General Medical Council (GMC), and General Pharmaceutical Council (GPhC), where applicable

• Care Quality Commission (CQC) regulatory expectations, including Regulations 9 and 17 of the Health and Social Care Act 2008 (Regulated Activities) Regulations

• Save Face professional standards and guidance for medical aesthetics clinics

• Joint Council for Cosmetic Practitioners (JCCP) standards and competency frameworks, where applicable

Legal, regulatory, editorial and compliance notice

(CAP Code Section 12 – Medicines, Medical Devices and Health)

1. Purpose and scope of content

All content published on this website, including blog posts, articles, and educational materials, is provided solely for general educational and informational purposes.

The content is intended to support public understanding of aesthetic medicine, clinical governance, professional standards, and patient safety.

This content is not designed, intended, or structured to advertise, promote, market, recommend, or sell prescription-only medicines, nor to induce or encourage the uptake of any medical or aesthetic treatment.

2. Prescription-only medicines and CAP Code compliance

Where prescription-only medicines, including botulinum toxin products, are referenced, such references are made strictly in an educational and explanatory context.

No prescription-only medicines are offered for sale, endorsed, promoted, compared for marketing purposes, or implied to be available for purchase within this content.

In accordance with UK law and the UK Advertising Standards Authority (ASA) CAP Code, including Section 12, this content contains no pricing information, promotional language, calls to action, incentives, or inducements relating to prescription-only medicines.

3. Separation of editorial content and clinical services

Blog posts and educational content published on this website do not contain links, booking prompts, or direct pathways to treatments, services, or commercial pages relating to procedures that require prescription-only medicines.

Any clinical services involving prescription-only medicines are accessed separately and only following an appropriate medical consultation, full clinical assessment, and lawful independent prescribing in accordance with UK legislation and professional regulatory requirements.

4. No medical advice, treatment direction or clinician–patient relationship

This content does not constitute medical advice, a diagnosis, a treatment recommendation, or a substitute for a clinical consultation.

Information is presented in general terms and may not be appropriate for all individuals.

Information within blog posts and educational materials must not be used to self-diagnose, self-direct, initiate, modify, delay, or replace medical or aesthetic treatment.

Nothing within this content creates, or should be interpreted as creating, a clinician–patient relationship.

Individual suitability for any treatment is determined exclusively following a formal consultation with a qualified healthcare professional.

5. Risk, outcomes and limitations

All aesthetic procedures carry risks and potential side effects.

Outcomes vary between individuals and no specific result, benefit, or duration of effect can be guaranteed.

Full information regarding risks, benefits, alternatives, aftercare, and potential complications will always be provided as part of the clinical consultation process.

6. Editorial independence

All editorial content is produced independently by the author.

Editorial decisions are not influenced by commercial considerations, treatment sales, product manufacturers, sponsors, or external commercial relationships.

No payment, incentive, or benefit is received in exchange for referencing any product, treatment, or clinical approach within editorial content.

7. Accuracy, jurisdiction and currency of information

The information contained within this content is accurate to the best of the author’s professional knowledge and understanding at the time of publication.

Some content reflects prevailing professional standards, published guidance, peer‑reviewed literature, or clinical consensus within aesthetic practice, including areas where the evidence base or regulatory guidance may be evolving.

Reference to specific products, brands, techniques, or third‑party materials is provided for explanatory purposes only and does not constitute endorsement, recommendation, or preference.

This content is written with reference to UK law, regulatory frameworks, and professional standards and may not be applicable in other jurisdictions.

Clinical practice, regulatory guidance, professional standards, and legal requirements may change over time.

Content may be reviewed, updated, amended, or withdrawn where accuracy, clarity, or compliance considerations arise.

8. Interpretation, reuse, platform use and limitation of liability

The company and the author accept no liability for reliance placed on this content outside of its intended educational and informational context.

Publication of educational content does not constitute an offer to provide treatment, create any obligation to supply services, or imply availability of any medical or aesthetic procedure.

The company and the author are not responsible for how this content is interpreted, reproduced, relied upon, summarised, extracted, modified, or presented when quoted, shared, or used outside its original published context, including by third-party platforms, automated systems, or artificial intelligence tools.

9. Ongoing compliance, interpretation and risk management

Language used within blog posts and educational materials is selected to prioritise clarity, accuracy, proportionality, and regulatory compliance.

Where wording, terminology, or framing may reasonably give rise to concern regarding interpretation, promotion, offence, or compliance with the CAP Code or other applicable standards, such content will be reviewed and amended as necessary.

Where any reference to a prescription-only medicine is made inadvertently, incidentally, or without intention to promote or advertise, such reference does not alter the educational and non-promotional nature of the content. Content will be reviewed and amended promptly where any potential compliance concern is identified.

Views expressed within editorial content reflect professional opinion and interpretation at the time of writing. Reasonable professional disagreement may exist, and alternative professional views may be equally valid.

Readers, regulators, professionals, or stakeholders who identify potential concerns regarding accuracy, clarity, interpretation, regulatory compliance, or professional standards are encouraged to raise these for review.

10. Application of this notice and audience

This content is intended for an adult audience and is published with safeguarding considerations in mind. Where content may be accessed by or relate to individuals under the age of 18, appropriate safeguarding principles apply.

This notice applies to all blog posts, articles, and educational materials published on this website.

It is intended to support ongoing compliance with the UK Advertising Standards Authority (ASA) and the CAP Code, including Section 12 relating to medicines, medical devices, and health-related advertising.